Specifically, we observed that JAK1/2 inhibition resulted in a pattern of immune signaling dysregulation different from controls or BC samples, with statistically significant increases in error rates and decreases in SNR observed in all cell types as compared to BC samples, with the notable exception of the error rates in CD4 + T cell subsets as relative to controls (Figs 5D and P in S1 Text). This evidence concerns the gene JAK1 and breast cancer.